Compare ACRS & SOPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACRS | SOPH |
|---|---|---|
| Founded | 2012 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 529.9M | 462.3M |
| IPO Year | 2015 | 2021 |
| Metric | ACRS | SOPH |
|---|---|---|
| Price | $3.45 | $6.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 5 |
| Target Price | ★ $9.82 | $9.75 |
| AVG Volume (30 Days) | ★ 2.6M | 666.6K |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.01 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,683,000.00 | N/A |
| Revenue This Year | N/A | $23.68 |
| Revenue Next Year | N/A | $24.29 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.46 | $4.01 |
| 52 Week High | $6.60 | $8.98 |
| Indicator | ACRS | SOPH |
|---|---|---|
| Relative Strength Index (RSI) | 39.18 | 37.40 |
| Support Level | $3.24 | $4.58 |
| Resistance Level | $4.60 | $6.54 |
| Average True Range (ATR) | 0.28 | 0.65 |
| MACD | -0.02 | -0.09 |
| Stochastic Oscillator | 17.03 | 13.13 |
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.